MA51844A - Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 - Google Patents
Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4Info
- Publication number
- MA51844A MA51844A MA051844A MA51844A MA51844A MA 51844 A MA51844 A MA 51844A MA 051844 A MA051844 A MA 051844A MA 51844 A MA51844 A MA 51844A MA 51844 A MA51844 A MA 51844A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- cancer treatment
- treatment methods
- ctla4
- ctla4 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862630038P | 2018-02-13 | 2018-02-13 | |
US201862732828P | 2018-09-18 | 2018-09-18 | |
US201862740741P | 2018-10-03 | 2018-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51844A true MA51844A (fr) | 2021-05-19 |
Family
ID=67620098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051844A MA51844A (fr) | 2018-02-13 | 2019-02-08 | Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210047409A1 (fr) |
EP (1) | EP3752193A4 (fr) |
JP (2) | JP2021513540A (fr) |
KR (1) | KR20200119845A (fr) |
CN (1) | CN111727056A (fr) |
AU (2) | AU2019222517A1 (fr) |
BR (1) | BR112020015915A8 (fr) |
CA (1) | CA3090996A1 (fr) |
MA (1) | MA51844A (fr) |
MX (1) | MX2020008446A (fr) |
WO (1) | WO2019160755A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2437327T3 (es) | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor PD-1 humano de muerte programada |
CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
JP2023515675A (ja) * | 2020-03-05 | 2023-04-13 | メルク・シャープ・アンド・ドーム・エルエルシー | Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 |
US20230092707A1 (en) * | 2020-03-05 | 2023-03-23 | Merck Sharp & Dohme Llc | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody |
WO2021213523A1 (fr) * | 2020-04-24 | 2021-10-28 | 信达生物制药(苏州)有限公司 | Utilisations d'une combinaison d'anticorps anti-pd-1 et d'anticorps anti-ctla-4 dans la prévention ou le traitement du cancer |
TW202305009A (zh) * | 2021-04-08 | 2023-02-01 | 美商默沙東有限責任公司 | 以皮下投予抗pd1抗體治療癌症之方法 |
KR20240099187A (ko) * | 2021-10-29 | 2024-06-28 | 온코씨4, 아이앤씨. | 항-ctla-4 항체 투여 요법 |
CN113933520B (zh) * | 2021-11-15 | 2023-06-20 | 邹灵龙 | 一种通用型抗体药血药浓度检测的单克隆抗体试剂组合、检测方法和试剂盒 |
WO2024002074A1 (fr) * | 2022-06-28 | 2024-01-04 | 齐鲁制药有限公司 | Composition pharmaceutique comprenant un anticorps mixte d'anti-ctla4 et anti-pd1 et son utilisation thérapeutique |
WO2024055005A2 (fr) * | 2022-09-09 | 2024-03-14 | Adagene Pte. Ltd. | Anticorps anti-ctla4 activables pour le traitement du cancer |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100942863B1 (ko) * | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
NZ563193A (en) * | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
ES2437327T3 (es) * | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor PD-1 humano de muerte programada |
AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
EP3185866A1 (fr) * | 2014-08-25 | 2017-07-05 | Pfizer Inc. | Combinaison d'un antagoniste de pd-1 et d'un inhibiteur d'alk dans le traitement du cancer |
EP3288980B1 (fr) * | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Traitement du mélanome pd-l1 positif à l'aide d'un anticorps anti-pd-1 |
SI3322731T1 (sl) * | 2015-07-14 | 2021-03-31 | Bristol-Myers Squibb Company | Postopek za zdravljenje raka z uporabo imunskega inhibitorja kontrolne točke; protitelo ki veže programiran receptor smrti (PD-1) ali programiran smrtni ligand 1 (PD-L1) |
EP3331918A1 (fr) * | 2015-08-04 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Polythérapies, leurs utilisations et méthodes associées |
WO2017025871A1 (fr) * | 2015-08-07 | 2017-02-16 | Glaxosmithkline Intellectual Property Development Limited | Polythérapie comprenant des anticorps anti-ctla-4 |
WO2017106656A1 (fr) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Molécules d'anticorps anti-pd-1 et leurs utilisations |
US10358496B2 (en) * | 2016-03-01 | 2019-07-23 | Ralf Kleef | Low dose immune checkpoint blockade in metastatic cancer |
PT3463457T (pt) * | 2016-06-02 | 2023-09-07 | Bristol Myers Squibb Co | Bloqueio de pd-1 com nivolumab em linfoma de hodgkin refratário |
WO2017210637A1 (fr) * | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Utilisation d'anticorps anti-pd-1 dans le traitement de patients atteints d'un cancer colorectal |
US20200325226A1 (en) * | 2016-06-03 | 2020-10-15 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treating a tumor |
EP3618866A4 (fr) * | 2017-05-02 | 2021-07-14 | Merck Sharp & Dohme Corp. | Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation |
-
2019
- 2019-02-08 CN CN201980013384.1A patent/CN111727056A/zh active Pending
- 2019-02-08 EP EP19754385.3A patent/EP3752193A4/fr active Pending
- 2019-02-08 WO PCT/US2019/017188 patent/WO2019160755A1/fr unknown
- 2019-02-08 JP JP2020542952A patent/JP2021513540A/ja active Pending
- 2019-02-08 MX MX2020008446A patent/MX2020008446A/es unknown
- 2019-02-08 KR KR1020207026005A patent/KR20200119845A/ko unknown
- 2019-02-08 BR BR112020015915A patent/BR112020015915A8/pt unknown
- 2019-02-08 AU AU2019222517A patent/AU2019222517A1/en not_active Abandoned
- 2019-02-08 US US16/966,988 patent/US20210047409A1/en active Pending
- 2019-02-08 CA CA3090996A patent/CA3090996A1/fr active Pending
- 2019-02-08 MA MA051844A patent/MA51844A/fr unknown
-
2023
- 2023-07-26 AU AU2023208115A patent/AU2023208115A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000161A patent/JP2024038250A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3752193A4 (fr) | 2022-02-23 |
CN111727056A (zh) | 2020-09-29 |
KR20200119845A (ko) | 2020-10-20 |
BR112020015915A2 (pt) | 2020-12-15 |
AU2019222517A1 (en) | 2020-08-13 |
RU2020129075A (ru) | 2022-03-14 |
MX2020008446A (es) | 2020-09-28 |
EP3752193A1 (fr) | 2020-12-23 |
US20210047409A1 (en) | 2021-02-18 |
WO2019160755A1 (fr) | 2019-08-22 |
JP2024038250A (ja) | 2024-03-19 |
CA3090996A1 (fr) | 2019-08-22 |
JP2021513540A (ja) | 2021-05-27 |
AU2023208115A1 (en) | 2024-01-18 |
BR112020015915A8 (pt) | 2023-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51844A (fr) | Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 | |
MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
MA52789A (fr) | Méthodes de traitement du cancer avec des anticorps anti-pd-1 | |
MA51631A (fr) | Anticorps anti-pd1 et méthodes de traitement | |
MA51208A (fr) | Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancer | |
MA47208A (fr) | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
SI3458478T1 (sl) | Anti-PD1 in anti-LAG3 protitelesa za zdravljenje raka | |
MA51815A (fr) | Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
MA53506A (fr) | Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules | |
EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
MA56212A (fr) | Compositions et méthodes de traitement du cancer | |
MA40576B1 (fr) | Anticorps et immunoconjugués anti-her2 | |
MA51677A (fr) | Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
BR112017009297A2 (pt) | anticorpos antifator de complemento c1q humanizados e usos dos mesmos | |
MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
MA47613A (fr) | Compositions et procédés de traitement du cancer | |
MA46842A (fr) | Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 | |
EA201990778A1 (ru) | Анти-il-33 антитела и их применение | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA45675A (fr) | Méthodes et compositions permettant le traitement du cancer | |
EA201790529A1 (ru) | Новые антитела против mfi2 и способы их применения | |
MA47362A (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif |